natgillin/translations-raw huggingface dataset:
Many pressurized aerosol packs contain a metered dose valve that accurately measures a single dose of the product within the pressurized reservoir. 
Mnoga stlačena pakovanja aerosola sadrže ventil za odmjeravanje doze koji precizno mjeri jednu dozu proizvoda stlačenog unutar spremnika.
The method of claim 2, wherein the compound has formula (III) or (IIIa) 
Spoj u skladu s patentnim zahtjevom 1 formule (III) ili (IIIa) HR P20140174 T1 2
The column was packed with MEP HyperCel® resin following the manufacturer's instructions. 
Kolona je bila spakirana s nosačem MEP HyperCel? prema uputama proizvođača.
An antibody or antigen-binding fragment thereof that specifically binds to a lysyl oxidase-like 2 (LOXL2) protein, and inhibits the enzyme activity of the LOXL2 protein, wherein the inhibition is non-competitive, which is an isolated antibody, wherein the antibody or fragment thereof competes for binding to LOXL2 with another antibody that specifically binds to a region of LOXL2 comprising SEQ ID NO: 6. 
Izolirano protutijelo ili njegov za antigen vezni fragment koji se veže za lizil oksidaza-sličan (LOXL2) protein, pri čemu se to protutijelo ili antigen vezni fragment specifično vežu za aminokiselinsku sekvencu SEQ ID NO:6 i inhibiraju enzimatsku aktivnost proteina LOXL2, pri čemu je inhibicija ne-kompetitivna.
The material according to claim 1, wherein the vinyl chloride copolymer and/or vinyl chloride terpolymer comprises acetate or acrylate groups. 
Materijal prema patentnom zahtjevu 1 naznačen time da se kopolimer vinil-klorida i/ili terpolimer vinil-klorida sastoje od acetatnih ili akrilatnih grupa.
A fermentation method comprising adding the starter culture of Claim 19 to a fermentation medium, under conditions such that fermentation of the components of said fermentation medium occur. 
Postupak fermentacije naznačen time da sadrži dodavanje starter kulture prema zahtjevu 19 u fermentacijski medij, pod takvim uvjetima da se javlja fermentacija komponenti navedenog fermentacijskog medija.
The invention provides the use of a compound according to the above or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of affective disorders, such as depression, anxiety disorders including general anxiety disorder, social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, panic disorder, panic attacks, specific phobias, social phobia and agoraphobia. 
Ovaj izum nudi uporabu spoja kao gore ili njegove farmaceutski prihvatljive kiselinske soli za pripravu lijeka za liječenje afektivnih poremećaja, poput depresije, poremećaja tjeskobe uključujući poremećaj opće tjeskobe, poremećaja socijalne tjeskobe, poremećaja post traumatskog stresa, opsesivno kumpulzivnog poremećaja, poremećaja panike, napadaje panike, specifičnih fobija, socijalne fobije i agorafobije
An antibody or antigen-binding fragment thereof that binds human CGRP receptor, said human CGRP receptor comprising a human CRLR polypeptide and a human RAMP1 polypeptide, wherein the antibody or antigen-binding fragment thereof binds to an epitope formed of amino acids residues from both CRLR and RAMP1 polypeptides, and wherein the antibody or antigen-binding fragment thereof competes for binding to human CGRP receptor with a reference antibody, said reference antibody comprising (i) a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 161, 163, 164, 166, and 168; and (ii) a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 140, 143, 146, 148, and 150. 
Monoklonsko protutijelo ili njegov antigen-vezujući fragment koji veže ljudski CGRP receptor, navedeni ljudski CGRP receptor obuhvaća ljudski CRLR polipeptid i ljudski RAMPI polipeptid, naznačeno time što se monoklonsko protutijelo ili njegov antigen-vezujući fragment veže za epitop formiran od aminokiselinskih ostataka iz oba polipeptida CRLR i RAMPI, te pri čemu se monoklonsko protutijelo ili njegov antigen-vezujući fragment natječe za vezanje na ljudski CGRP receptor s referentnim protutijelom, pri čemu navedeno referentno protutijelo sadrži (i) varijabilnu regiju teškog lanca koja sadrži sekvencu odabranu iz skupine koja se sastoji od SEQ ID NOs: 161, 163, 164, 166, 1 168; i (11) varijabilnu regiju laganog lanca koja sadrži sekvencu odabranu iz skupine koja se sastoji od SEQ ID NOs: 140, 143, 146, 148, i 150.
conducting arylation of the prepared compound of formula 39 with a compound of formula R1-H (or, a step of deprotecting R1 may be comprised): wherein, in formulas 38 to 42, X1, X2, X3, X4, R1, R2, R3, R4 and R5 are the same as defined in formula 1; and Z represents a reactive leaving group. 
provođenje arilacije pripremljenog spoja s formulom 39 sa spojem s formulom R1-H (ili, može sadržavati korak deprotekcije R1): pri čemu, u formulama 38 do 42, X1, X2, X3, X4, R1, R2, R3, R4 i R5 su isti kako je definirano u formuli 1; i Z predstavlja reaktivnu odlazeću skupinu.
The box-shaped collar is composed of four perpendicular walls, whose front edge acts as reference plane for wall scraping, meaning that the wall is plastered in such a way that its surface is perfectly flush with the front edge of the box-shaped collar. 
Okvir koji ima oblik kutije je sastavljen od četiri okomite stijenke, čiji prednji rub djeluje kao referentna ravnina za uređenje zida, znači daje na zid nanesena žbuka na takav način da je njegova površina savršeno izravnana s prednjim rubom okvira koji ima oblik kutije.
The compound of item 1, wherein said compound has the (E)-configuration at the oxime group comprised in formula (I). 
Spoj prema zahtjevu 1, naznačen time što navedeni spoj ima (E)-konfiguraciju na oksim skupini sadržanoj u formuli (I).
The compound of one of preceding claims 1-2, wherein R7 is selected from the group consisting of H, methoxy, ethoxy, and an optionally substituted morpholinyl ring. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se skupinu R3 bira iz skupine koju čine H, metil, te trifluormetil.
to react with a compound of formula Ib: thereby giving, upon optional deprotection, a compound of formula (B) as defined in claim 1. 
HN-< Ib te se tako dobiva, nakon proizvoljnog uklanjanja zaštite, spoj s formulom (B) kako je definirano u zahtjevu 1.
After overnight shaking, compound 1-4 was purified by prep. LC-MS. 
Nakon tresenja preko noći spoj 1-4 pročisti se preparativnim sustavom LC-MS.
The process according to claim 1, wherein the separation step is a flash or a distillation. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je korak razdvajanja spaljivanje ili destiliranje.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
Apparatus according to claim 1, wherein the propelling means drives comprises a rail system, a cable system, a self-propelled system, a robotic system, a system guided from a distance, a boat with an engine, a floating device with an engine, or a combination thereof. 
Uređaj za obradu vode uz nizak trošak, prema bilo kojem prethodnom zahtjevu, naznačen time što pogonsko sredstvo (6) za pokretanje sadrži tračnički sustav, kabelski sustav, samohodni sustav, robotski sustav, daljinski vođen sustav, brod s motorom, plutajući uređaj s motorom, ili njihovu kombinaciju.
p is 1. In yet another aspect, the present invention provides compounds of formula (I) in free or salt form, wherein 
Također, u drugom obliku predloženi izum osigurava spojeve formule (1) u slobodnom obliku ili u obliku soli, u kojoj formuli
The pharmaceutical according to claim 11 for use in preventing or treating a TNF-a-related disease, wherein the TNF-a-related disease is one or more selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus (SLE), lupus nephritis, systemic scleroderma, localized scleroderma, Sjogren's syndrome, polymyositis, dermatomyositis, ulcerative colitis, Crohn's disease, Behcet's disease, multiple sclerosis, arteriosclerosis, myasthenia gravis, ankylosing spondylitis, diabetes, arteriosclerosis, sepsis, acute infectious diseases, asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, contact dermatitis, psoriasis, acne, osteoporosis, burns, the onset of rejection associated with organs or tissue transplantation, fever, anemia, cancer, periodontal disease, glaucoma, diabetic complications, and uveitis. 
Farmaceutski pripravak prema patentnom zahtjevu 11 za upotrebu u prevenciji ili liječenju bolesti povezanih s TNF-a, naznačen time da je bolest povezana s TNF-a jedna ili više bolest iz grupe bolesti koja uključuje reumatoidni artritis, posorijatični artritis, sistemski eritemski lupus (SLE), lupus nefritis, sistemsku skelodermiju, lokalnu skelodermiju, Sjorgenov sindrom, polimiozitis, dermatomiozitis, ulcerativni kolitis, Kronovu bolest, Behcetovu bolest, multiplu sklerozu, arteriosklerozu, mijasteniju gravis, ankilozantni spondilitis, dijabetis, arteriosklerozu, sepsu, akutnu infekciju, astmu, kroničnu opstruktivnu bolest pluća (COPD), atopijski dermatitis, kontaktni dermatitis, psorijazu, akne, osteosporozu, opekline, napad ili odbacivanje povezano s transplantacijom organa ili tkiva, vrućicu, anemiju, rak, paradontozu, glaukom, dijabetičke komplikacije 1 uveitis.
A compound of Formula II of claim 1 represented by Formula VI: or an acceptable salt, thereof; 
Spoj Formule II u skladu s patentnim zahtjevom 1 predstavljen Formulom VI:
An antibody, or binding fragment thereof, according to any one of claims 1 to 12 or 16 for administration alone or in combination with additional antibodies, chemotherapeutic drugs, radiation therapy or therapeutic vaccines. 
Protutijelo ili njegov fragment za vezanje, za uporabu prema bilo kojem od patentnih zahtjeva 10 do 15, naznačen/o time, da uporaba obuhvaća davanje protutijela ili njegovog fragmenta za vezanje, samoga ili u kombinaciji s dodatnim protutijelima, kemoterapeutskim lijekovima, radijacijskom terapijom ili terapeutskim cjepivima.
The method according to claim 1 or 2 wherein said albumin is human albumin, and is advantageously of serum origin. 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time da je spomenuti albumin ljudski albumin, 1 preporučuje se da potječe iz seruma.
flavours; a vegetable and/or animal extract or powder. 
– ekstraktom ili prahom biljnog i/ili životinjskog podrijetla.
A method for producing a protein or a polypeptide in a bacteria host cell, wherein the protein or the polypeptide is free of norleucine misincorporation, the method comprising expressing in the bacteria host cell a nucleic acid encoding the protein or the polypeptide under culture conditions suitable to allow for expression of the protein or the polypeptide, wherein the bacteria host cell comprises a mutant metA allele, a mutant metK allele, or a mutant metA allele and a mutant metK allele, thereby producing a protein or a polypeptide free of norleucine misincorporation. 
Postupak za proizvodnju proteina ili polipeptida koji ne sadrži pogrešno ugrađeni norleukin u bakterijskoj domaćinskoj stanici, naznačen time, da je protem ili polipeptid bez pogrešno ugrađenog norleukina, dok postupak obuhvaća eksprimiranje nukleinske kiseline u bakterijskoj domaćinskoj stanici koja kodira protein ili polipeptid u uvjetima uzgoja prikladnima za eksprimiranje proteina ili polipeptida, pri čemu bakterijska domaćinska stanica obuhvaća mutantni metA alel koji sadrži nukleinskokiselinsku sekvencu ID BR. SEK.:24.
The process according to claim 14, wherein the isolated polypeptide with esterase activity comprises the amino acid sequence shown in SEQ ID NO: 2. 
Postupak prema zahtjevu 14 ili 15, naznačen time da izolirani polipeptid s aktivnošću esteraze sadrži sekvencu amino kiseline prikazanu u SEQ ID No. 2.
Fig. 2 shows a system in which a capsule is placed on the capsule holder but has not yet reached its closing position in the beverage production device, 
prikazuje sustav u kojemu je čahura postavljena na držač čahure, ali još nije dostigla svoj zatvoreni položaj u uređaju za pripremanje napitka,
The pharmaceutical formulation for use according to claim 8 or 9 wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, lung cancer, and colorectal cancer. 
Farmaceutska formulacija za uporabu prema zahtjevu 8 ili 9, naznačena time, da je rak odabran iz skupine koja se sastoji od raka dojke, raka jajnika, raka pluća 1 kolorektalnog raka.
The reaction was diluted with water (50 mL) and extracted with ethyl acetate (3×50 mL). 
Reakcija je razrijeđena vodom (50 mL) i ekstrahirana etil acetatom (3 x 50 mL).
Different methods for producing the form I of donepezil hydrochloride are described. However, no specific solid pharmaceutical compositions are disclosed, let alone data on the stability of donepezil hydrochloride, either in the amorphous or in the different crystal forms, when incorporated in such a composition. 
Opisani su različiti postupci pripreme donepezil hidroklorida oblika I. Ipak, u isti nisu uključeni posebni farmaceutski pripravci, a kamoli podaci o stabilnosti donepezil hidroklorida, bilo u amorfnoj ili u različitim kristalnim oblicima, kada čini sastavni dio spomenutog farmaceutskog pripravka.
at least one phosphate salt; the method comprising: aa) dissolving the compound of the formula (III) and/or (II): 
(II) i b) najmanje jednu fosfatnu sol i izborno NaCI; naznačen time što se postupak sastoji u: aa) otapanju spoja formule (III) i/ili (ID):
calculating the sum of the telomere component, the dosage component and a constant; and 
Postupak prema zahtjevu 4, pri čemu je komponenta duljine telomere pozitivna komponenta prilikom računanja postotka promjene.
The pharmaceutical composition for use according to claim 20, wherein the administration of the glatiramer acetate is effected subcutaneously and the administration of rasagiline or the pharmaceutically acceptable salt thereof is effected orally. 
Farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 20, naznačen time, da se davanje glatiramer acetata provodi supkutano, a davanje rasagilina ili njegove farmaceutski prihvatljive soli se provodi oralno.
a suction system (804) suitable to remove, from the road platform, the above resulting emulsion (806), obtained from polluting materials mixed to the washing/treatment solution (803); furthermore, solid and not biodegradable debris are removed/aspirated, these debris being related to typical car equipments (805); 
- < sistemom za usisavanje (804) prikladnim da s cestovne plohe odstrani gornju nastalu emulziju (806) dobivenu iz zagađujućih tvari pomiješanih s otopinom za ispiranje/obradu (803); osim toga, krute i nebiorazgradive krhotine koje su odstranjene ili usisane, a povezane s tipičnom opremom automobila (805);
at least one alkylamine alkoxylate surfactant where R is a straight- or branched-chain alkyl or alkenyl group having from 8 to 22 carbon atoms; B is ethylene or propylene; and n and n' are integers such that n+n' has a value of 2 to 12. 
/ (BO),H R-N . \(BO),H gdje R je ravnolančana ili razgranata alkilna ili alkenilna skupina koja ima od 8 do 22 ugljikovih atoma; B je etilen ili propilen; te su n in' cijeli brojevi tako da n+n' ima vrijednost od 2 do 12.
The sulfide compounds may be prepared as diacids (though this may involve intermediate protection of the glutamyl a-carboxyl as well as the amine) or as mono- or diesters, depending on the state of the starting amino acids. 
HR P20090134 T3 Sulfidni spojevi mogu se pripraviti kao dikiseline (premda ovo može uključiti zaštitu intermedijera glutamila a-karboksila kao amina) ili kao mono- ili diestera, ovisno o stanju početne amino kiseline.
The present invention relates to compounds of formula (I) 
PATENTNI ZAHTJEVI Tvar formule (IT) gdje
• X represents two hydrogen atoms; and 
X predstavlja dva atoma vodika; i
reagent (Q1-reag) is selected from the group consisting of lithium, magnesium, aluminum, zinc, calcium, isopropylmagnesium chloride, isopropylmagnesium bromide, butyllithium, sec-butylithium and mixtures thereof; 
Reagens (Ql-reag.) je odabran iz skupine koja se sastoji iz litija, magnezija, aluminija, cinka, kalcija, izopropilmagnezijklorida, izopropilmagnezijbromida, butillitija, sec-butillitija i njihovih mješavina;
In the present invention, the metered dose valve 2 allows the user to select three positions: 
U predloženom izumu, ventil za odmjeravanje doze 2 omogućuje korisniku da odabere tri položaja:
A crystal solvate according to claim 1 characterized by a XRPD displaying a peak at diffraction angle 2θ of 19.9 ± 0.1. 
Kristalni solvat u skladu s patentnim zahtjevom 1, naznačen time što XRPD pokazuje vršni kut kod difrakcije 20 od 199 +01.
A medicinal cream as claimed in claims 1 and 3 to 6 further comprising a humectant which is selected from a group comprising Glycerin, Sorbitol, Propylene Glycol and the like, or any combination thereof, and added in an amount from about 5% (w/w) to 50% (w/w). 
Medicinska krema prema patentnim zahtjevima 1 1 3 do 6, naznačena time, da nadalje sadrži ovlaživač koji se odabire iz skupine koja sadrži glicerin, sorbitol, propilenglikol 1 slične, ili bilo koju njihovu kombinaciju 1 dodaje u količini od oko 5% (tež.) do 50% (tež.).
The compound of any one of embodiments 1-23, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage, at least one modified sugar, or at least one modified nucleobase. 
Spoj prema zahtjevu 1, gdje modificirani oligonukleotid sadrži barem jednu modificiranu internukleozidnu vezu, barem jedan modificirani šećer, ili barem jednu modificiranu nukleobazu, opcionalno gdje modificirana internukleozidna veza je fosforotioatna internukleozidna veza.
The antibody of any one of claims 1 to 3 or obtainable by the method of claim 7 for use in the prophylaxis or treatment of inflammatory and thrombotic disorders according to claim 10, wherein said disorder is peripheral arterial occlusive disease (PAOD) or critical limb ischemia (CLI). 
Protutijelo prema bilo kojem zahtjevu od 1 do 4 ili 9, naznačeno time, da se upotrebljava za profilaksu ili liječenje upalnih 1 trombotičkih poremećaja prema zahtjevu 13, pri čemu je spomenuti poremećaj okluzivna bolest perifernih arterija (PAOD) ili opasna ishemija ekstremiteta (CLI).
The pharmaceutical composition of claim 1, wherein Ar1 and/or Ar2 are selected from phenyl, pyridyl, pyrimidyl, imidazolyl, pyrazolyl, thiophenyl, or triazolyl. 
Farmaceutska kompozicija iz patentnog zahtjeva 1, gdje Ar; i/ili Ar, su odabrani od fenil, piridil, pirimidil, imidazolil, pirazolil, tiofenil, triazolil.
TLK199, identified in those patents and publications as TER 199, is the diethyl ester of TLK117. U.S. Pat. 
TLK 199, je dietil ester od TLK 117; dok su TLK 261 1 TLK 262 dimetil i diizopropil esteri, pojedinačno.
The computer program product of claim 1, wherein the contents of the second location includes an amount of data to be stored. 
Postupak prema zahtjevu 1, gdje sadržaj druge lokacije obuhvaća količinu podataka koji će se pohraniti.
3 comprises 3 plates, it can comprise 1 to about 10 plates, and specifically about 2 to about 6 plates. 
Izmjenjivač topline s pokretnim slojem prema zahtjevu 1, naznačen time da mjerna prigušnica sadrži 2 do oko 10 ploča.
providing a Neisseria meningitidis serogroup A polysaccharide; 
(a) osiguravanje nativnog polisaharida iz bakterije Neisseria meningitidis seroskupina A;
In some preferred embodiments, at least a portion of the CRISPR locus of the parent bacterial strain and at least a portion of the modified CRISPR locus of the bacteriophage resistant variant strain are compared by sequencing at least a portion of the CRISPR locus and at least a portion of the modified CRISPR locus. 
Postupak prema zahtjevu 1, naznačen time da se navedeni barem dio navedenog CRISPR lokusa navedenog matičnog bakterijskog soja i barem dio navedenog modificiranog CRISPR lokusa navedenih varijanti sojeva rezistentnih na bakteriofage uspoređuju sekvenciranjem barem dijela navedenog CRISPR lokusa i barem dijela navedenog modificiranog CRISPR lokusa.
Cocoa-derived material according to any of claims 1 to 9, wherein said soluble cocoa powder comprises an amount of glucose, glucose oligomers and/or dextrines comprised between 10 and 60% by fat-free dry weight. 
Tvar dobivena iz kakaa u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time, da dotični topljivi prašak kakaa sadrži maseni udjel glukoze, oligomera glukoze i/ili dekstrina u rasponu od 10 do 60 % u suhom, odmašćenom stanju.
A composition according to claim 5, wherein R3 is selected from ethylenediamine and cyclohexanediamine. A composition according to claim 6, wherein R3 is cyclohexanediamine. 
Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1 naznačen time da je R3 odabran od etilendiamina i cikloheksandiamina.
Evaporation of the appropriate fractions gave the product as an off-white solid (270 mg, 96%); 
Otparivanjem odgovarajućih frakcija dobiven je produkt u obliku blijedo bijele boje (270 mg, 96 %);
mixing the solution resulting from step (iv) with fat phase in order to obtain the low fat spread. 
(v) miješanje otopine dobivene u koraku (iv) s masnom fazom radi dobivanja namaza s niskim sadržajem masti.
An agent for use according to any one of claims 1 to 6 wherein the fructose intolerance is intestinal fructose intolerance. 
Sredstvo sukladno bilo kojem od patentnih zahtjeva 1 do 6, naznačeno time da je netolerancija fruktoze petoterancija crijevne fruktoze.
The compound for use according to claim 1, wherein tipifarnib is administered at a dose of 1-1000 mg/kg body weight or wherein tipifarnib is administered at a dose of 600 mg twice a day or at a dose of 900 mg twice a day. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu je tipifarnib primijenjen u dozi od 1-1000 mg/kg tjelesne mase ili pri čemu je tipifarnib primijenjen u dozi od 600 mg dva puta dnevno ili u dozi od 900 mg dva puta dnevno.
In a preferred embodiment, a fusion polypeptide is administered with one or more adjuvants selected from the group consisting of 3D-MPL and QS21 in a liposome formulation eg AS01B and MPL and QS21 and an oil in water emulsion (eg AS02A). 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što se adjuvans bira iz skupine koju čine 3D-MPL i QS21 u liposomskoj formulaciji i 3D-MPL, QS21 i emulzija tipa ulje u vodi.
In accordance with another preferred embodiment two rock bolts may be joined and thereby provide a longer rock bolt. 
U skladu s drugom preferiranom izvedbom dva se sidra u stijeni mogu spojiti i na taj način dati dulje sidro u stijeni.
Upon deoxygenation or elimination-reduction as described above for compound VII, compounds XXI may be transformed into compounds XXII for which R6—R9 are as defined above, and Q is an sulfonyl ester as described for compounds XI. 
Nakon dezoksigenacije ili eliminacija-redukcije prema gornjem opisu za spoj VII, spojevi XXI mogu sc transformirati u spojeve XXII za koje su R"-R? prema gornjem opisu, a Q je sulfonil ester prema opisu za spojeve XI.
wherein R2a is hydrogen, lower alkyl optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, heterocycle lower alkyl optionally substituted by substituent group C, or —Z—N(RB9)(RB10) 
R* je vodik, niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, karbociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, heterociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, ili